Dementia with Lewy bodies

5 trials 4 recruiting MedDRA PT
5 Registered trials
4 Recruiting
4 Unique sponsors
4 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
N Neurology/Psychiatry (ATC N) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 1 Phase II: 3 Phase I: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Acadia Pharmaceuticals Inc. Commercial
    ACP-204 TARTRATE
    2025-521711-39-00 4 countries 2026 n=49
    Recruiting

Phase II

3 trials
  • Acadia Pharmaceuticals Inc. Commercial
    ACP-204 TARTRATE
    2025-521710-25-00 4 countries 2025 n=77
    Recruiting
  • Eip Pharma Inc. Commercial
    NEFLAMAPIMOD
    2024-511446-39-00 1 country 2024 n=25
    Ended
  • Region Skane Academic
    2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE; FLUTEMETAMOL (18F)
    2024-511842-38-00 1 country 2017 n=2,450
    Recruiting

Phase I

1 trial
  • AC Immune S.A. Commercial
    IMP not specified
    2024-515664-31-00 1 country 2025 n=46
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Acadia Pharmaceuticals Inc. Commercial 2 Phase II, Phase III 2
AC Immune S.A. Commercial 1 Phase I 1
Eip Pharma Inc. Commercial 1 Phase II 0
Region Skane Academic 1 Phase II 1
New trials by year
2024
1
2025
2
2026
1
← All indication landscapes